Natural phospholipase A2 myotoxin inhibitor proteins from snakes, mammals and plants

Toxicon

Volumn 42, Issue 8, 2003, Pages 963-977

  Lizano, Sergio ^a   Domont, Gilberto ^b   Perales, Jonas ^c  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antitoxic protein; Myotoxin; Phospholipase A2

Indexed keywords

ALPHA1 GLYCOPROTEIN; ALPHA1 GLYCOPROTEIN B; CASEARIA SYLVESTRIS EXTRACT; CROTALUS NEUTRALIZING FACTOR; CROTOXIN; CYSTATIN; DM 40; DM 43; DM 64; IMMUNOGLOBULIN; METALLOPROTEINASE INHIBITOR; NEUROTOXIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE A2 INHIBITOR ALPHA; PHOSPHOLIPASE A2 INHIBITOR BETA; PHOSPHOLIPASE A2 INHIBITOR GAMMA; PLANT MEDICINAL PRODUCT; SNAKE VENOM; UNCLASSIFIED DRUG; VEGETABLE PROTEIN;

ANAPHYLAXIS; BOTHROPS ASPER; CASEARIA; CASEARIA SYLVESTRIS; DEFENSE MECHANISM; DRUG ISOLATION; DRUG STRUCTURE; ENVENOMATION; HUMAN; IMMUNITY; IMMUNOGENICITY; INFLAMMATION; MAMMAL; MEDICINAL PLANT; MULTIGENE FAMILY; MUSCLE INJURY; MUSCLE NECROSIS; MUSCLE TISSUE; NEUROTOXICITY; NONHUMAN; OPOSSUM; PLANT; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SNAKE; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; WITHANIA SOMNIFERA;

DIDELPHIDAE; MAMMALIA; NAJA NAJA; SERPENTES; WITHANIA SOMNIFERA;

EID: 1042287027     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2003.11.007     Document Type: Article

References (98)

1. Abbas A.K., Lichtman A.H., Pober J.S. Cellular and Molecular Immunology. Saunders W.B. 1991;4-6 HBJ International Edition, Philadelphia.
2. Aird S.D., Kaiser I.I., Lewis R.V., Kruggel W.G. A complete amino acid sequence for the basic subunit of crotoxin. Arch. Biochem. Biophys. 249:1986;296-300.
3. Aird S.D., Yates J.R. III, Martino P.A., Shabanowitz J., Hunt D.F., Kaiser I.I. The amino acid sequence of the acidic subunit B-chain of crotoxin. Biochim. Biophys. Acta. 1040:1990;217-224.
4. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:1997;3389-3402.
5. 2 from Bothrops asper snake venom. Toxicon. 39:2001;879-887.
6. 2 - a structural review. Toxicon. 34:1996;827-841.
7. 2. Comp. Biochem. Physiol. B. 127:2000;21-30.
8. Cardoso J.L.C., Fan H.W., França F.O.S., Jorge M.T., Leite R.P., Nishioka S.A., Avila A., Sano-Martins I.S., Tomy S.C., Santoro M.L., Chudzinski A.M., Castro S.C.B., Kamiguti A.S., Kelen E.M.A., Hirata M.H., Mirandola R.M.S., Theakston R.D.G., Warrell D.A. Randomized comparative trial of three antivenoms in treatment of envenoming by lance-head vipers (Bothrops jararaca) in São Paulo. Braz. Q. J. Med. 86:1993;315-325.
9. Chippaux J.P. Snake-bites: appraisal of the global situation. Bull. WHO. 76:1998;515-524.
10. Chippaux J.P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon. 36:1998;823-846.
11. Deepa M., Gowda T.V. Purification and characterization of a glycoprotein inhibitor of toxic phospholipase from Withania somnifera. Arch. Biochem. Biophys. 408:2002;42-50.
12. 2 neurotoxins on Torpedo synaptosomes. J. Neurochem. 58:1992;311-319.
13. 2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1997;1-2.
14. 2 in eicosanoid generation. Am. J. Respir. Crit. Care Med. 161:2000;532-535.
15. 2: role of negatively charged phospholipids as potential membrane binding sites. Arch. Biochem. Biophys. 391:2001;56-64.
16. Domont G.B., Perales J., Moussatché H. Natural anti-snake venom proteins. Toxicon. 29:1991;1183-1194.
17. Drickamer K. C-type lectin-like domains. Curr. Opin. Struct. Biol. 9:1999;585-590.
18. Drickamer K., Taylor M.E. Biology of animal lectins. Annu. Rev. Cell Biol. 9:1993;237-264.
19. 2. Biochimie. 82:2000;833-840.
20. 2 with the crotoxin inhibitor from Crotalus serum. Eur. J. Biochem. 106:2000;4799-4808.
21. 2 by lung surfactant protein A (SP-A). Biochim. Biophys. Acta. 1211:1994;256-262.
22. Fontana F. Traité sur le venin de la Vipère, sur les poisons Américaines, sur le laurier-cerise et sur quelques autres poisons vegetaux, Florence, Italy. Gibelin. 1781.
23. 2 in the blood plasma of snakes. Toxicon. 40:2002;481-484.
24. Fortes-Dias C.L., Fonseca B.C.B., Diniz C.R., Kochva E. Purification and properties of an antivenom factor from the plasma of the South American rattlesnake (Crotalus durissus terrificus). Toxicon. 29:1991;997-1008.
25. 2 inhibitor from the plasma of the South American rattlesnake (Crotalus durissus terrificus). J. Biol. Chem. 269:1994;15646-15651.
26. 2 from Lachesis muta muta snake venom. Toxicon. 37:1999;1747-1759.
27. Fox J.W., Bjarnason J.B. Metalloproteinase inhibitors. Bailey G.S. Enzymes from Snake Venoms. 1998;599-632 Alaken Inc, Fort Collins, CO.
28. 2 myotoxins from Bothrops snake venoms. Toxicon. 33:1995;1405-1424.
29. Gutiérrez J.M., Rucavado A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie. 82:2000;841-850.
30. Gutiérrez J.M., Lomonte B., Chaves F., Moreno E., Cerdas L. Pharmacological activities of a toxic phospholipase A isolated from the venom of the snake Bothrops asper. Comp. Biochem. Physiol. 84C:1986;159-164.
31. 2 inhibitors from Australian elapid sera. Biochem. J. 346:2000;139-146.
32. 2 inhibitor from Notechis ater serum. J. Biol. Chem. 275:2000;983-991.
33. 2 inhibitor from the serum of the common tiger snake (Notechis scutatus). J. Mol. Biol. 312:2001;875-884.
34. Hawgood B. Abbe Felice Fontana [1730-1805]: founder of modern toxinology. Toxicon. 33:1995;591-601.
35. 2 inhibitors from the plasma of venomous snakes. Biochem. Mol. Biol. Int. 41:1997;529-537.
36. Ishioka N., Takahashi N., Putnam F.W. Amino acid sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin supergene family. Proc. Natl Acad. Sci. USA. 83:1986;2363-2367.
37. 2 receptor. J. Biol. Chem. 269:1994;5897-5904.
38. Kihara H. Studies on phospholipase A in Trimeresurus flavoviridis venom. Purification and some properties of phospholipase A inhibitor in habu venom. J. Biochem. (Tokyo). 80:1976;341-349.
39. Kini R.M., Kawabata S.I., Iwanaga S. Structure-function relationships of phospholipases. II: Charge density distribution and the myotoxicity of presynaptically neurotoxic phospholipases. Toxicon. 24:1986;895-905.
40. 2 inhibitor from the blood plasma of Trimeresurus flavoviridis. J. Biochem. (Tokyo). 106:1989;966-971.
41. 2 ammodytoxin and crotoxin bind to distinct high-affinity protein acceptors in Torpedo marmorata electric organ. Biochemistry. 36:1997;2779-2787.
42. Lambeau G., Barhanin J., Schweitz H., Qar J., Lazdunski M. Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom. J. Biol. Chem. 264:1989;11503-11510.
43. 2 in skeletal muscle. J. Biol. Chem. 265:1990;9526-9532.
44. 2 in different tissues. Neurochem. Res. 16:1991;651-658.
45. 2. TIPS. 102:1999;162-170.
46. 2. J Biol. Chem. 269:1994;1575-1578.
47. 2 myotoxins from the plasma of the snake of Bothrops asper. Biochem. J. 326:1997;853-859.
48. 2 myotoxins from its own venom: isolation, molecular cloning, and biological properties. Biochem. J. 346:2000;631-639.
49. 2 myotoxin isoforms from Bothrops asper. Int. J. Biochem. Cell Biol. 33:2001;127-132.
50. 2 of Bothrops asper snake venom. Toxicon. 32:1994;1359-1369.
51. 2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. J. Biol. Chem. 269:1994;29867-29873.
52. 2 on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells in vitro. Toxicon. 37:1999;145-158.
53. Mebs D., Ownby C.L. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmac. Ther. 48:1990;223-236.
54. Mebs D. Enzymes in snake venom: an overview. Bailey G.S. Enzymes from Snake Venom. 1998;1-10 Alaken Inc, Fort Collins, CO.
55. Melo P.A., Suarez-Kurtz G. Release of sarcoplasmic enzymes from skeletal muscle by Bothrops jararacussu venom: antagonism by heparin and by the serum of South American marsupials. Toxicon. 26:1988;87-95.
56. Middleton E. Jr. Effect of plant flavonoids on immune and inflammatory cell function. Adv. Exp. Med. Biol. 439:1998;175-182.
57. Mishra L.C., Singh B.B., Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev. 5:2000;334-346.
58. Moussatché H., Perales J. Factors underlying the natural resistance of animals against snake venoms. Mem. Inst. Oswaldo Cruz. 84:1989;391-394.
59. Neves-Ferreira A.G.C., Cardinale N., Rocha S.L.G., Perales J., Domont G.B. Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum. Biochim. Biophys. Acta. 1474:2000;309-320.
60. Neves-Ferreira A.G.C., Perales J., Fox J.W., Shannon J.D., Makino D.L., Garratt R.C., Domont G.B. Structural and functional analyses of DM43, a snake venom metalloproteinase inhibitor from Didelphis marsupialis serum. J. Biol. Chem. 277:2002;13129-13137.
61. 2 inhibitors from the serum of Trimeresurus flavoviridis snake. Gene. 191:1997;31-37.
62. 2 isozymes in the snake's venom. Eur. J. Biochem. 249:1997;838-845.
63. 2 isozymes. FEBS Lett. 429:1998;385-389.
64. Noel L.S., Champion B.R., Holley C.L., Simmons C.J., Morris D.C., Payne J.A., Lean J.M., Chambers T.J., Zaman G., Lanyon L.E., Suva L.J., Miller L.R. RoBo-1, a novel member of the urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family selectively expressed in rat bone and growth plate cartilage. J. Biol. Chem. 273:1998;3878-3883.
65. Norrdin R.W., Jee W.S., High W.B. The role of prostaglandins in bone in vivo. Prostagl. Leukot. Essent. Fatty Acids. 41:1990;139-149.
66. 2 from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. Toxicon. 39:2001;1587-1594.
67. 2. J. Mol. Evol. 41:1995;867-877.
68. 2 inhibitor from the blood plasma of Agkistrodon blomhoffii siniticus. J. Biochem. (Tokyo). 113:1993;413-419.
69. 2 inhibitor from the blood plasma of the Thailand cobra, Naja naja kaouthia. Biochem. Biophys. Res. Commun. 200:1994;784-788.
70. 2 inhibitor from the plasma of Thailand cobra having structural similarity to urokinase-type plasminogen activator receptor and LY-6 related proteins. Biochem. Biophys. Res. Commun. 204:1994;1212-1218.
71. 2 inhibitors from the blood plasma of the Chinese mamushi, Agkistrodon blomhoffii siniticus. Biochem. J. 325:1997;527-531.
72. 2 inhibitor from the blood plasma of the sea krait, Laticauda semifasciata. J. Biochem. 125:1999;375-382.
73. Ohsaka A. Hemorragic, necrotizing and edema-forming effects of snake venoms. Lee C.Y. Snake Venoms. 1979;480-546 Springer, Berlin.
74. 2 inhibitor with leucine-rich repeats from the blood plasma of Agkistrodon blomhoffii siniticus: Sequence homologies with human leucine-rich α2-glycoprotein. J. Biol. Chem. 273:1998;19469-19475.
75. 2 inhibitor from the serum of the non-venomous snake Elaphe quadrivirgata. Biochem. J. 341:1999;165-171.
76. 2 inhibitor in a nonvenomous snake, Elaphe quadrivirgata. Arch. Biochem. Biophys. 408:2002;124-130.
77. Omori-Satoh T., Yamakawa Y., Mebs D. The antihemorrhagic factor, erinacin, from the European hedgehog (Erinaceus europaeus), a metalloprotease inhibitor of large molecular size possessing ficolin/opsonin P35 lectin domains. Toxicon. 38:2000;1561-1580.
78. Ownby C.L. Structure, function and biophysical aspects of the myotoxins from snake venoms. J. Toxicol. Toxin Rev. 17:1998;213-238.
79. Perales J., Villela C.G., Domont G.B., Choumet V., Saliou B., Moussatché H., Bon C., Faure G. Molecular structure and mechanism of action of the crotoxin inhibitor from Crotalus durissus terrificus serum. Eur. J. Biochem. 227:1995;19-26.
80. Perales J., Villela C.G., Chermont S., Domont G.B., Moussatché H., Faure G., Bon C. Caracterização parcial do complexo entre inibidor da crotoxina isolado do soro da cascavel e a subunidade CB desta toxina. Abstract Book, X Reunião Anual da Federação de Sociedades de Biologia Experimental, São Paulo, Brazil. 1995;P330.
81. 2 and myotoxins members of the innate immune system? Ménez A. Perspectives in Molecular Toxinology. 2002;435-456 Wiley, Chichester.
82. Pérez J.C., Sánchez E.E. Natural protease inhibitors to hemorrhagins in snake venoms and their potential use in medicine. Toxicon. 37:1999;703-728.
83. Phisalix M. Masson, Cie. Immunité contre lê venin in Animaux Venimeux et Venins. 1922;744-759 Libraires de L'Académie de Médicine.
84. 2 inhibitors from marine organisms. J. Nat. Prod. 55:1992;1701-1717.
85. Qi Z.-Q., Yonaha K., Tomihara Y., Toyama S. Characterization of the antihemorrhagic factors of mongoose (Herpestes edwardsii). Toxicon. 32:1994;1459-1469.
86. Qi Z.-Q., Yonaha K., Tomihara Y., Toyama S. Isolation of peptides homologous to domains of human alpha 1B-glycoprotein from a mongoose antihemorrhagic factor. Toxicon. 33:1995;241-245.
87. Rawlinson S.C., El-Haj A.J., Minter S.L., Tavares I.A., Bennett A., Lanyon L.E. Loading-related increases in prostaglandin production in cores of adult canine cancellous bone in vitro: a role for prostacyclin in adaptive bone remodeling? J. Bone Miner. Res. 6:1991;1345-1351.
88. Rocha S.L.G., Lomonte B., Neves-Ferreira A.G.C., Domont G.B., Gutiérrez J.M., Perales J. Functional analysis of DM64, an antimyotoxic protein with immunoglobulin-like structure from Didelphis marsupialis serum. Eur. J. Biochem. 269:2002;6052-6062.
89. 2 activity of growth zone and resting zone cartilage cells in vitro. Endocrinology. 122:1988;2191-2198.
90. 2 activity by 1,25-(OH)2D3 in three osteoblast-like cell lines (MC-3T3-E1, ROS 17/2.8, and MG-63). Bone (NY). 13:1992;51-58.
91. 2 from Bothrops venoms by the heteromeric protein complex of Didelphis albiventris opossum serum. Biochem. Mol. Biol. Int. 43:1997;1091-1099.
92. 2 myotoxin inhibitor protein from Bothrops moojeni plasma. Biochem. Biophys. Res. Comm. 302:2003;193-200.
93. Theakston R.D.G. Snake bite: the kinetics of envenoming and therapy. Bon C., Goyffon M. Envenomings and Their Treatments. 1996;117-126 Éditions Fondation Marcel Mérieux, Lyon.
94. Thwin M.-M., Gopalakrishnakone P. Snake envenomation and protective natural endogenous proteins: a mini review of the recent developments (1991-1997). Toxicon. 36:1998;1471-1482.
95. 2 inhibition and venom neutralizing potential. Biochemistry. 39:2000;9604-9611.
96. 2 binding and anti-inflammatory activity. Eur. J. Biochem. 269:2002;719-727.
97. Valente R.H., Dragulev B., Perales J., Fox J.W., Domont G.B. BJ46a, a snake venom metalloproteinase inhibitor. Isolation, characterization, cloning and insights into its mechanism of action. Eur. J. Biochem. 268:2001;3042-3052.
98. Warrell D.A. Clinical features of envenoming from snake bites. Bon C., Goyffon M. Envenomings and Their Treatments. 1996;63-76 Editions Fondation Marcel Mérieux, Lyon.